Deupirfenidone Shows Promise Against IPF-Linked Lung Decline

Deupirfenidone Shows Promise Against IPF-Linked Lung Decline

Tweaking the pirfenidone molecule yields an evidently effective but less toxic antifibrotic drug, investigators say.

Rein Therapeutics doses first subject in Phase II trial to treat IPF

Rein Therapeutics has dosed the first subject in a Phase II trial of LTI-03, its lead asset for treating idiopathic pulmonary fibrosis (IPF).The post Rein Therapeutics doses first subject in Phase II trial to treat IPF appeared first on Clinical Trials Arena.

Patients With IPF Face QOL Challenges With Antifibrotic Treatment

Patients reported that side effects often impacted their quality of life (QOL). However, most patients said their treatment helped slow disease progression and gave them hope.

Breakthrough IPF Drug Enters Phase 2 Trial: Rein's Novel Treatment Could Transform Pulmonary Fibrosis Care

Novel multi-pathway IPF treatment begins Phase 2 trial across 50 global sites. 120-patient study evaluating breakthrough Caveolin-1 therapy. See interim data timeline.

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026